Pharmacological effects Biological Activity Indications Dosage Side effects Other clinical research
ChemicalBook > CAS DataBase List > Ruxolitinib

Ruxolitinib

Pharmacological effects Biological Activity Indications Dosage Side effects Other clinical research
Product Name
Ruxolitinib
CAS No.
941678-49-5
Chemical Name
Ruxolitinib
Synonyms
Jakafi;Roxolitinib;(R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile;(R)-Ruxolitinib;CS-163;Pridazole;Rusotinib;Russolinib;Benzalolin;Ruxolitinib
CBNumber
CB02499581
Molecular Formula
C17H18N6
Formula Weight
306.37
MOL File
941678-49-5.mol
More
Less

Ruxolitinib Property

Melting point:
84-89°C
Density 
1.40
storage temp. 
-20°
solubility 
Soluble in DMSO (up to 28 mg/ml) or in Ethanol (up to 15 mg/ml with warming).
form 
White powder.
pka
11.63±0.50(Predicted)
color 
White
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.
InChI
InChI=1/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/s3
InChIKey
HFNKQEVNSGCOJV-UJHUVDBMNA-N
SMILES
[C@@H](C1CCCC1)(N1N=CC(C2N=CN=C3NC=CC=23)=C1)CC#N |&1:0,r|
CAS DataBase Reference
941678-49-5
More
Less

Safety

HS Code 
29335990
Hazardous Substances Data
941678-49-5(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H302Harmful if swallowed

Precautionary statements

P202Do not handle until all safety precautions have been read and understood.

P280Wear protective gloves/protective clothing/eye protection/face protection.

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
11609
Product name
Ruxolitinib
Purity
≥98%
Packaging
1mg
Price
$25
Updated
2024/03/01
Cayman Chemical
Product number
11609
Product name
Ruxolitinib
Purity
≥98%
Packaging
5mg
Price
$69
Updated
2024/03/01
Cayman Chemical
Product number
11609
Product name
Ruxolitinib
Purity
≥98%
Packaging
10mg
Price
$125
Updated
2024/03/01
Cayman Chemical
Product number
11609
Product name
Ruxolitinib
Purity
≥98%
Packaging
25mg
Price
$250
Updated
2024/03/01
Tocris
Product number
7064
Product name
Ruxolitinib
Purity
≥98%(HPLC)
Packaging
50
Price
$229
Updated
2021/12/16
More
Less

Ruxolitinib Chemical Properties,Usage,Production

Pharmacological effects

Myelofibrosis (MF) is a rarely-occurring disease of myelodysplastic disorders. It is caused by the replacement of in vivo bone marrow by scar tissue, leading to the production of blood cells in the liver and spleen and other organs, which is characterized by splenomegaly, anemia, leukopenia, and thrombocytopenia, and different degrees of bone sclerosis. Symptoms include fatigue, abdominal discomfort, pain under the ribs, muscle and bone pain, itching and night sweats.
Ruxolitinib is the first oral medication approved by the US Food and Drug Administration (FDA) for the treatment of myelofibrosis. It is a small-molecule inhibitor of the tyrosine kinase (namely, JAK1 and JAK2) and is suitable for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia Vera myelofibrosis and post essential thrombocythemia myelofibrosis.
August 29, 2012, the EU has approved the first drug for the treatment of myelofibrosis, ruxolitinib. Ruxolitinib can be used for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia Vera myelofibrosis and post essential thrombocythemia myelofibrosis. Currently, ruxolitinib has been approved by more than 50 countries around the world, including the EU, Canada and some Asian, Latin American and South American countries.
US Novartis has obtained authorization from Incyte Company of the development and commercialization right of Ruxolitinib outside the United States. The European Commission and the FDA have both granted the status of Ruxolitinib as the orphan drug in the treatment of myelofibrosis. Currently, Incyte has sold it under the trade name Jakafi in the United States for the treatment of intermediate or high-risk myelofibrosis.

Figure 1 is the ruxolitinib tablet produced by the US Novartis Company (trade name: Jakafi)

Biological Activity

Ruxolitinib, INCB18424 is a potent and selective JAK1 and JAK2 inhibitor (IC50 were 2.7 and 4.5nM, respectively). It has potent anti-tumor and immunomodulatory activity. Ruxolitinib can inhibit IL-6 signal (IC50 = 281nM) and the proliferation of JAK2V617F + Ba/F3 cell. Ruxolitinib can also inhibit the STA3 phosphorylation of wild-type JAK2 and JAK2 V617F mutant inside the body of patients. Clinical application of it can significantly cause reduction in the circulating levels of inflammatory cytokines. Ruxolitinib also has an effective role in model of the adjuvant arthritis and the multiple-cause murine arthritis.
This information is edited by Xiongfeng Dai from Chemicalbook.

Indications

Ruxolitinib is a kind of kinase inhibitor which is suitable for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia Vera myelofibrosis and post essential thrombocythemia myelofibrosis.

Dosage

1. For patients with platelet counts being greater than 200/μl, ruxolitinib should be applied at a start dose of 20 mg with being administered orally twice per day while for patients with platelet counts between 100/μl and 200/μl, they should apply a dose of 15mg twice a day.
2. Before starting to apply ruxolitinib treatment, you should perform complete blood count. Monitor the complete blood count in every 2-4 weeks and lower the adjusted dose for platelet count.
3. According to the result of the reaction, the patients can increase the dose to the maximum recommended dose of 25 mg twice per day. The patient should discontinue if the spleen gets no reduction or the symptoms are not improved, the patients should discontinue after 6 months.

Side effects

The most common hematological adverse reactions (incidence> 20%) is lower platelet counts and anemia. The most common non-hematologic adverse reactions (incidence> 10%) are bruising, dizziness and headache.

Other clinical research

Columbia University Medical Center has conducted a test of a drug designed to treat bone marrow diseases to investigate whether it can help people get rid of alopecia areata. The study found that, for human participating in human body test, including seven women and five men, after they have administrated a drug called Ruxolitinib, the symptoms of most people has been greatly alleviated. Part of their research has been published in the "Nature Medicine" magazine.

Description

In November 2011, the U.S. FDA approved ruxolitinib (INCB018424) for the treatment of patients with intermediate or high-risk myelofibrosis. Ruxolitinib is an ATP-competitive inhibitor of JAK1 and JAK2 (IC50's of 3.3±1.2 nM and 2.8±1.2 nM, respectively) and inhibition occurs regardless of the JAK2V617F mutational status. Ruxolitinib is a moderately potent inhibitor of the related JAK, TYK2 (IC50=19±3.2 nM) but is selective versus JAK3 (IC50=428±243 nM). It was also selective versus a panel of 26 other kinases at concentrations approximately 100-fold the IC50 of JAK1 and JAK2. Inhibition of JAK1 and JAK2 downregulates the JAK-signal transducer and activator of transcription (STAT) pathway, inhibiting myeloproliferation, inducing apoptosis, and reducing numerous cytokine plasma levels.

Originator

Incyte Corporation (United States)

Characteristics

Class: non-receptor tyrosine kinase
Treatment: MF, PV, cGVHD
Oral bioavailability >95%
Elimination half-life = 3 h
Protein binding = 97%

Uses

Janus-associated kinases (JAKs) are cytoplasmic tyrosine kinases that are required for activating the signaling of certain cytokines and growth factor receptors. A JAK2 gene fusion mutation, JAK2V617F, that causes unchecked activation of various growth factors and cytokines, has been linked to myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Ruxolitinib is a potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5 nM, respectively and is relatively less selective for JAK3 (IC50 = 322 nM). It can block interleukin-6 (IL-6) signaling (IC50 = 281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127 nM). In primary cultures, ruxolitinib preferentially suppresses erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67 nM) versus healthy donors (IC50 > 400 nM). In a mouse model of JAK2V617F+ MPN, 90 mg/kg ruxolitinib reduced splenomegaly, decreased circulating levels of IL-6 and TNF-α, eliminated neoplastic cells, and prolonged survival of the treated animals.[Cayman Chemical]

Uses

A JAK family kinase inhibitor of JAK1, JAK2 and JAK3 with IC50s of 2.7 nM, 4.5 nM and 322 nM, respectively

Uses

Ruxolitinib is a selective Janus tyrosine kinase (JAK1 and JAK2) inhibitor used in the treatment of myeloproliferative neoplasms and psoriasis.

Uses

INCB018424 is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. Phase 3

Definition

ChEBI: A pyrazole substituted at position 1 by a 2-cyano-1-cyclopentylethyl group and at position 3 by a pyrrolo[2,3-d]pyrimidin-4-yl group. Used as the phosphate salt for the treatment of patients with intermediate or high-risk myelofibrosis, includ ng primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.

Indications

The JAK family includes four isoforms, JAK1, JAK2, JAK3, and tyrosine kinase (TYK2). Ruxolitinib (Jakafi(R), Incyte Corp.) was the first approved JAK inhibitor, which inhibits both JAK1 and JAK2, used for the treatment of different types of myelofibrosis. Tofacitinib (Xeljanz(R), Pfizer) was approved by FDA as a JAK3-selective inhibitor for the treatment of rheumatoid arthritis and is one of the only two FDA-approved kinase inhibitors for non-oncological indications.

brand name

Jakafi

Clinical Use

Tyrosine kinase inhibitor:
Treatment of disease related splenomegaly or symptoms in patients with primary myelofibrosis (MF), post polycythaemia vera (PV) myelofibrosis or post-essential thrombocythemia myelofibrosis

target

JAK1

Drug interactions

Potentially hazardous interactions with other drugs
Antibacterials: concentration increased by clarithromycin and telithromycin, reduced dose of ruxolitinib; concentration reduced by rifampicin.
Antifungals: reduce dose of ruxolitinib with fluconazole, itraconazole, ketoconazole, posaconazole and voriconazole.
Antipsychotics: avoid with clozapine, risk of agranulocytosis.
Antivirals: reduce dose of ruxolitinib with boceprevir, indinavir, lopinavir, ritonavir, saquinavir and telaprevir.

Metabolism

Ruxolitinib is mainly metabolised by CYP3A4 (>50%), with additional contribution from CYP2C9 to produce 2 major and active metabolites. About 74% of a dose is excreted in the urine and about 22% via the faeces.

storage

Store at -20°C

References

1) Verstovsek?et al. (2009),?Therapeutic potential of JAK2 inhibitors; Hematology Am. Soc. Hematol. Educ. Program,?2009(1)?636 2) Quintas-Cardama?et al. (2010),?Preclinical characterization of the selective JAK1/2 inhibitor INCB01824: Therapeutic implications for the treatment of myeloproliferative neoplasms; Blood,?115?3109 3) Farr et al. (2017) Targeting cellular senescence prevents age-related bone loss in mice; Nat. Med. 23 1072 4) Li?et al.?(2017)?Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia; Oncotarget?8?34687

Ruxolitinib Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Ruxolitinib Suppliers

Nanjing zehe Pharmaceutical Technology Co., Ltd
Tel
17768115366
Email
henry124604479@163.com
Country
China
ProdList
251
Advantage
58
Anqing Benro pharmachem Technology Co.,Ltd.
Tel
05565209906 15391842992
Email
794263564@qq.com
Country
China
ProdList
115
Advantage
58
Nanjing Qiya Pharmaceutical Co., Ltd.
Tel
025-85451006; 18795969897
Email
3066995499@qq.com
Country
China
ProdList
83
Advantage
58
Changzhou Yongfeng Biomedicine Co. Ltd.
Tel
15006117673
Fax
2973592490@.com
Email
2973592490@qq.com
Country
China
ProdList
306
Advantage
58
Yunfei Pharmaceutical(Shenzhen) Co., Ltd.
Tel
0755-61160828 15994832653
Fax
0755-61160828
Email
hulixiu@yunfeipharma.com
Country
China
ProdList
248
Advantage
58
Shanghai Youna Biopharmaceutical Co., Ltd
Tel
18164002430
Email
511710754@qq.com
Country
China
ProdList
228
Advantage
58
Wuhan Juchengyuan Biotechnology Co., Ltd
Tel
400-0276007 18062142210
Email
804180422@qq.com
Country
China
ProdList
140
Advantage
58
Shanghai Boyle Chemical Co., Ltd.
Tel
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2922
Advantage
55
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6005
Advantage
61
More
Less

View Lastest Price from Ruxolitinib manufacturers

airuikechemical co., ltd.
Product
Ruxolitinib 941678-49-5
Price
US $0.00-0.00/Kg
Min. Order
1Kg
Purity
99.9%
Supply Ability
200tons
Release date
2024-04-09
Wuhan Senwayer Century Chemical Co.,Ltd
Product
Ruxolitinib 941678-49-5
Price
US $0.00/KG
Min. Order
1KG
Purity
99%
Supply Ability
20 TONS
Release date
2022-11-07
Hebei Fengjia New Material Co., Ltd
Product
Ruxolitinib 941678-49-5
Price
US $5.00/kg
Min. Order
1kg
Purity
0.99
Supply Ability
1000
Release date
2024-09-04

941678-49-5, RuxolitinibRelated Search:


  • (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
  • (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile
  • (3R)-3-(4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
  • (3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyriMidin-4-yl}-1H-pyrazol-1-yl)propanenitrile
  • INCB018424 (Ruxolitinib)
  • Jakafi
  • Roxolitinib
  • β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-(βR)-1H-pyrazole-1-propanenitrile
  • (R)-Ruxolitinib
  • (βR)-β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazole-1-propanenitrile
  • Ruxolitinib(INCB-018424)
  • 1H-Pyrazole-1-propanenitrile,.beta.-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-,(.beta.R)-
  • Ruxolitinib
  • Ruxolitinib INCB018424 Jakafi
  • Jakafi Ruxolitinib (INCB018424)
  • (R)-Ruxolitinib (>90%)
  • (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile Ruxolitinib(INCB018424)
  • R-Ruxolitinib (R-INCB018424)
  • Ruxolitinib, >=98%
  • Ruxolitinib free base
  • 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-pyrazol-1-yl]-propionitrile
  • (R)-Ruxolitinib (INCB018424)
  • Russolinib
  • CS-163
  • BETAR-?CYCLOPENTYL-?4-?(7H-?PYRROLO[2,?3-?D]PYRIMIDIN-?4-?YL)-?1H-?PYRAZOLE-?1-?PROPANENITRILE
  • RUXOLITINIB (INCB18424)
  • (R)-Ruxolitinib (&gt
  • 1H-Pyrazole-1-propanenitrile, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βR)-
  • Ruxolitinib ISO 9001:2015 REACH
  • β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(βR)-1H-pyrazole-1-propanenitrile
  • Benzalolin
  • Pridazole
  • Ruxolitinib(Jakafi)
  • JAK,INCB 18424,inhibit,Mitochondrial Autophagy,Mitophagy,INCB18424,Janus kinase,Autophagy,Apoptosis,INCB-18424,Ruxolitinib,Inhibitor
  • INCB018424(Ruxolitinib)/Ruxolitinib
  • (βR)-β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile
  • 2H9]-Rac-Ruxolitinib
  • Rusotinib
  • 941678-49-5
  • 971648-49-5
  • 52606144-44-7
  • JAK
  • STAT
  • Inhibitors
  • Anti-cancer&immunity
  • Inhibitor
  • APIs
  • Aromatics
  • Chiral Reagents
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Tyrosine Kinase Inhibitors
  • Antineoplastic
  • API